New vaccine shows promise for rare eye cancer
NCT ID NCT04335890
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested a personalized vaccine made from a patient's own immune cells and tumor material for people with metastatic uveal melanoma, a rare eye cancer that has spread. The vaccine was added to standard treatments like immunotherapy or chemotherapy. The main goals were to check safety and tolerability, with 17 participants enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA, UVEAL METASTATIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Hospital Erlangen Dept. of Dermatology
Erlangen, Bavaria, 91054, Germany